METASTATIC CASTRATION SENSITIVE PROSTATE CANCER (MCSPC)

Clinical trials for METASTATIC CASTRATION SENSITIVE PROSTATE CANCER (MCSPC) explained in plain language.

Never miss a new study

Get alerted when new METASTATIC CASTRATION SENSITIVE PROSTATE CANCER (MCSPC) trials appear

Sign up with your email to follow new studies for METASTATIC CASTRATION SENSITIVE PROSTATE CANCER (MCSPC), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Trials to join now! 1 Completed 2

New hope for prostate cancer: major trial tests drug combo to delay disease progression

Disease control Recruiting now

This study aims to see if adding an experimental drug called mevrometostat to the standard treatment enzalutamide works better for men with metastatic prostate cancer that still responds to hormone therapy. It will involve about 1,000 participants who have not yet received certai…

Matched conditions: METASTATIC CASTRATION SENSITIVE PROSTATE CANCER (MCSPC)

Phase: PHASE3 • Sponsor: Pfizer • Aim: Disease control

Last updated Mar 30, 2026 14:30 UTC

METASTATIC CASTRATION SENSITIVE PROSTATE CANCER (MCSPC)

Get alerted when new METASTATIC CASTRATION SENSITIVE PROSTATE CANCER (MCSPC) trials appear

New hope for prostate cancer: major trial tests drug combo to delay disease progression